Have a personal or library account? Click to login
Atrial Fibrillation and Acute Myocardial Infarction – An Inflammation-Mediated Association Cover

Atrial Fibrillation and Acute Myocardial Infarction – An Inflammation-Mediated Association

Open Access
|Nov 2018

References

  1. 1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847. doi: 10.1161/ CIRCULATIONAHA.113.005119.10.1161/CIRCULATIONAHA.113.005119415130224345399
  2. 2. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142-1147. doi: 10.1016/j.amjcard.2013.05.063.10.1016/j.amjcard.2013.05.06323831166
  3. 3. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807-1824. doi: 10.1016/j.ijcard.2012.12.093.10.1016/j.ijcard.2012.12.09323380698
  4. 4. Oldgren J, Healey JS, Ezekowitz M, et al. RE-LY Atrial Fibrillation Registry Investigators. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation. 2014;129:1568-1576. doi: 10.1161/CIRCULATIONAHA.113.005451.10.1161/CIRCULATIONAHA.113.00545124463370
  5. 5. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2017;00:1-66. doi:10.1093/eurheartj/ehx393.10.1093/eurheartj/ehx39328886621
  6. 6. Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J. 2000;140:878-885.10.1067/mhj.2000.11110811099991
  7. 7. Romanov A, Martinek M, Pürerfellner H, et al. Incidence of atrial fibrillation detected by continuous rhythm monitoring after acute myocardial infarction in patients with preserved left ventricular ejection fraction, results of the ARREST study. Europace. 2017;8:344. doi: 10.1093/europace/euw344.10.1093/europace/euw34428069838
  8. 8. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;39:1038-1045. doi: 10.1093/eurheartj/ehn579.10.1093/eurheartj/ehn57919109347
  9. 9. Rathore SS, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh BJ. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation. 2000;101:969-974.10.1161/01.CIR.101.9.969
  10. 10. Kea B, Alligood T, Manning V, Raitt M. A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome. Current emergency and hospital medicine reports. 2016;4:107-118. doi: 10.1007/s40138-016-0105-2.10.1007/s40138-016-0105-2523242128090403
  11. 11. McManus DD, Huang W, Domakonda KV, et al. Trends in Atrial Fibrillation in Patients Hospitalized with an Acute Coronary Syndrome. The American Journal of Medicine. 2012;125:1076-1084. doi: 10.1016/j.amjmed.2012.05.024.10.1016/j.amjmed.2012.05.024352451523098864
  12. 12. Angeli F, Reboldi G, Garofoli M, et al. Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. Curr Cardiol Rep. 2012;14:601-610. doi: 10.1007/s11886-012-0289-3.10.1007/s11886-012-0289-322821004
  13. 13. Jabre P, Roger VL, Murad MH, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and metaanalysis. Circulation. 2011;123:1587-1593. doi: 10.1161/ CIRCULATIONAHA.110.986661.10.1161/CIRCULATIONAHA.110.986661308277321464054
  14. 14. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-76.
  15. 15. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133:e38-e360. doi: 10.1161/cir.0000000000000350.10.1161/cir.0000000000000350
  16. 16. Ghushchyan V, Nair KV, Page RL 2nd. Indirect and direct costs of acute coronary syndromes with comorbid atrial fibrillation, heart failure, or both. Vasc Health Risk Manag. 2015;11:25-34. doi: 10.2147/VHRM.S72331.10.2147/VHRM.S72331428404725565859
  17. 17. Lau DH, Alasady M, Brooks AG, Sanders P. New-onset atrial fibrillation and acute coronary syndrome. Expert Rev Cardiovasc Ther. 2010;8:941-948. doi: 10.1586/erc.10.61.10.1586/erc.10.6120602555
  18. 18. Rubenstein JC, Cinquegrani MP, Wright J. Atrial Fibrillation in Acute Coronary Syndrome. Journal of Atrial Fibrillation. 2012;5:551. doi: 10.4022/jAF.551.10.4022/jAF.551
  19. 19. Anne W, Willems R, Roskams T, et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res. 2005;67:655-666. doi: 10.1016/j.cardiores.2005.04.016.10.1016/j.cardiores.2005.04.01615913581
  20. 20. Nguyen BL, Fishbein MC, Chen LS, Chen PS, Masroor S. Histopathological substrate for chronic atrial fibrillation in humans. Heart Rhythm. 2009;6:454-460. doi: 10.1016/j. hrthm.2009.01.010.10.1016/j.hrthm.2009.01.010266213419324302
  21. 21. Spach MS, Josephson ME. Initiating reentry: the role of non-uniform anisotropy in small circuits. J Cardiovasc Electrophysiol. 1994;5:182-209.10.1111/j.1540-8167.1994.tb01157.x
  22. 22. Greiser M. Calcium signalling silencing in atrial fibrillation. J Physiol. 2017;595:4009-4017. doi: 10.1113/JP273045.10.1113/JP273045547136228332202
  23. 23. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50:e1- e88. doi: 10.1093/ejcts/ezw313.10.1093/ejcts/ezw313
  24. 24. Jalife J, Kaur K. Atrial Remodeling, Fibrosis and Atrial Fibrillation. Trends in cardiovascular medicine. 2015;25:475-484. doi: 10.1016/j.tcm.2014.12.015.10.1016/j.tcm.2014.12.015
  25. 25. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015;36:3250-3257. doi: 10.1093/ eurheartj/ehv513.10.1093/eurheartj/ehv513
  26. 26. Alasady M, Lau D, Brooks A, et al. Atrial ischemia rather than neurohormonal or hemodynamic changes associ¬ated with acute myocardial infarction results in substrate for atrial fibrillation. Heart, Lung and Circulation. 2010;19:S2. doi: 10.1016/j.hlc.2010.06.66810.1016/j.hlc.2010.06.668
  27. 27. Alasady M, Abhayaratna WP, Leong DP, et al. Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction. Heart Rhythm. 2011;8:955-960. doi: 10.1016/j. hrthm.2011.02.016.10.1016/j.hrthm.2011.02.016
  28. 28. Ferreira JP, Santos M. Heart failure and atrial fibrillation: from basic science to clinical practice. Int J Mol Sci. 2015;16:3133-3147. doi: 10.3390/ijms16023133. 29. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847. doi: 10.1093/eurheartj/ehs104.10.3390/ijms16023133.29.etal.ESC2012:2012.(HFA)ESC.J.2012;33:1787-1847.doi:10.1093/eurheartj/ehs104
  29. 30. Kober L, Swedberg K, McMurray JJ, et al. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure of left ventricular dysfunction. Eur J Heart Fail. 2006;8:591-598. doi: 10.1016/j.ejheart.2005.11.007.10.1016/j.ejheart.2005.11.007
  30. 31. Kochiadakis GE, Skalidis EI, Kalebubas MD, et al. Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans. Eur Heart J. 2002;23:734-741. doi: 10.1053/euhj.2001.2894.10.1053/euhj.2001.2894
  31. 32. Ariyarajah V, Malinski M, Khadem A, et al. Relation of recurrence of atrial fibrillation after non-ST-elevation acute myocardial infarction to left atrial abnormality. Am J Cardiol. 2008;101:30-34. doi: 10.1016/j.amjcard.2007.07.044.10.1016/j.amjcard.2007.07.044
  32. 33. Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: A vicious electromechanical cycle. Circulation. 2004;109:2839-2843. doi: 10.1161/01. CIR.0000132470.78896.A8.10.1161/01.CIR.0000132470.78896.A8
  33. 34. De Jong AM, Maass AH, Oberdorf-Maass SU, et al. Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. Cardiovasc Res. 2011;89:754-765. doi: 10.1093/cvr/cvq357.10.1093/cvr/cvq357
  34. 35. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60:2263-2270. doi: 10.1016/j.jacc.2012.04.063.10.1016/j.jacc.2012.04.06323194937
  35. 36. Liuba L, Ahlomroth H, Jonasson L, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace. 2008;10:848-53. doi: 10.1093/europace/eun111.10.1093/europace/eun11118523031
  36. 37. Li J, Solus J, Chen Q, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm. 2010;7:438-444. doi: 10.1016/j.hrthm.2009.12.009.10.1016/j.hrthm.2009.12.009284377420153266
  37. 38. Pan M, Zhu JH, Jiang WP, et al. Inflammation: a possible pathogenic link to atrial fibrillation. Med Hypotheses. 2006;67:1305-1307. doi: 10.1016/j.mehy.2006.05.034.10.1016/j.mehy.2006.05.03416824699
  38. 39. Aronson D, Boulos M, Suleiman A, et al. Relation of C-reactive protein and new-onset atrial fibrillation in patients with acute myocardial infarction. Am J Cardiol. 2007;100:753-757. doi: 10.1016/j.amjcard.2007.04.014.10.1016/j.amjcard.2007.04.01417719315
  39. 40. Hwang HJ, Ha JW, Joung B, et al. Relation of inflammation and left atrial remodeling in atrial fibrillation occurring in early phase of acute myocardial infarction. Int J Cardiol. doi: 10.1016/j. ijcard.2009.05.065.10.1016/j.ijcard.2009.05.06519570585
  40. 41. Ma CY, Xu ZY, Wang SP, et al. Change of Inflammatory Factors in Patients with Acute Coronary Syndrome. Chinese Medical Journal. 2018;131:1444-1449. doi: 10.4103/0366-6999.233953.10.4103/0366-6999.233953600681129893361
  41. 42. Meuwissen M, van der Wal AC, Siebes M, et al. Role of plaque inflammation in acute and recurrent coronary syndromes. Netherlands Heart Journal. 2004;12:106-109.
  42. 43. Centurion OA. Serum biomarkers and source of inflammation in acute coronary syndromes and percutaneous coronary interventions. Cardiovasc Revasc Med. 2016;17:119-128. doi: 10.1016/j.carrev.2016.01.005.10.1016/j.carrev.2016.01.00526905055
  43. 44. Fang L, Moore XL, Dart AM, Wang LM. Systemic inflammatory response following acute myocardial infarction. Journal of Geriatric Cardiology: JGC. 2015;12:305-312. doi: 10.11909/j.issn.1671-5411.2015.03.020.
  44. 45. Frangogiannis NG. The inflammatory response in myocardialinjury, repair and remodeling. Nature Reviews Cardiology. 2014;11:255-265. doi: 10.1038/nrcardio.2014.28.10.1038/nrcardio.2014.28440714424663091
  45. 46. Sukhija R, Fahdi I, Garza L, et al. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. Am J Cardiol. 2007;99:879-884. doi: 10.1016/j. amjcard.2006.11.032.10.1016/j.amjcard.2006.11.03217398176
  46. 47. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circulation Research. 2012;110:159-273. doi: 10.1161/CIRCRESAHA.111.243162.10.1161/CIRCRESAHA.111.243162369013522223212
  47. 48. Seropian IM, Toldo S, Van Tassell BW, Abbate A. Antiinflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol. 2014;63:1593-1603. doi: 10.1016/j.jacc.2014.01.014.10.1016/j.jacc.2014.01.01424530674
  48. 49. Westman PC1, Lipinski MJ1, Luger D, et al. Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. J Am Coll Cardiol. 2016;67:2050-2060. doi: 10.1016/j.jacc.2016.01.073.10.1016/j.jacc.2016.01.07327126533
  49. 50. De Servi S, Mariani M, Mariani G, Mazzone A. C-reactive protein increase in unstable coronary disease cause or effect? J Am Coll Cardiol. 2005;46:1496-1502. doi: 10.1016/j.jacc.2005.05.083.10.1016/j.jacc.2005.05.08316226174
  50. 51. Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses. 2004;62:499-506. doi: 10.1016/j. mehy.2003.12.014.10.1016/j.mehy.2003.12.01415050096
  51. 52. van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med. 2003;163:1323-1328. doi: 10.1001/ archinte.163.11.1323.10.1001/archinte.163.11.132312796068
  52. 53. Sheikh AS, Yahya S, Sheikh NS, et al. C-reactive protein as a predictor of adverse outcome in patients with acute coronary syndrome. Heart Views. 2012;13:7-12. doi: 10.4103/1995-705X.96660.10.4103/1995-705X.96660338519722754634
  53. 54. Valgimigli M, Ceconi C, Malagutti P, et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study. Circulation. 2005;111:863-870. doi: 10.1161/01.CIR.0000155614.35441.69.10.1161/01.CIR.0000155614.35441.6915699251
  54. 55. Andrie RP, Becher UM, Frommold R, et al. Interleukin-6 is the strongest predictor of 30-day mortality in patients with cardiogenic shock due to myocardial infarction. Crit Care. 2012;16:R152.10.1186/cc11467358074122889197
  55. 56. Dayawansa NH, Gao XM, White DA, et al. Role of MIF in myocardial ischaemia and infarction: insight from recent clinical and experimental findings. Clin Sci. 2014;127:149-161. doi: 10.1042/CS20130828.10.1042/CS2013082824697297
  56. 57. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005;26:2083-2092. doi: 10.1093/eurheartj/ehi350.10.1093/eurheartj/ehi35015975993
  57. 58. Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006;27:136-149. doi: 10.1093/eurheartj/ehi645.10.1093/eurheartj/ehi64516278230
  58. 59. Patel P, Dokainish H, Tsai P, Lakkis N. Update on the association of inflammation and atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21:1064-1070. doi: 10.1111/j.1540-8167.2010.01774.x.10.1111/j.1540-8167.2010.01774.x20455973
  59. 60. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180-1184.10.1161/01.CIR.96.4.11809286947
  60. 61. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108:3006-3010. doi: 10.1161/01.CIR.0000103131.70301.4F.10.1161/01.CIR.0000103131.70301.4
  61. 62. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886-2891.10.1161/hc4901.10176011739301
  62. 63. Kallergis EM, Manios EG, Kanoupakis EM, et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart. 2008;94:200-204. doi: 10.1136/hrt.2006.108688.10.1136/hrt.2006.10868817575330
  63. 64. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J. 2008;155:303-309. doi: 10.1016/j.ahj.2007.09.006.10.1016/j.ahj.2007.09.006224736618215601
  64. 65. Floria M, Barboi O, Rezus C, et al. Atrial Fibrillation and Gastro-Oesophageal Reflux Disease - Controversies and Challenges. Curr Pharm. 2015;21:3829-3834.10.2174/138161282166615031910000325786404
  65. 66. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50:2021-2028. doi: 10.1016/j.jacc.2007.06.054.10.1016/j.jacc.2007.06.05418021867
  66. 67. Pellegrino PL, Brunetti ND, Gennaro LD, Ziccardi L, Grimaldi M, Biase MD. Inflammatory activation in an unselected population of subjects with atrial fibrillation: links with structural heart disease, atrial remodeling and recent onset. Intern Emerg Med. 2011;8:123-128. doi: 10.1007/s11739-011- 0557-z.10.1007/s11739-011-0557-z
  67. 68. Marcus GM, Smith L, Ordovas K, et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm. 2010;7:149-154. doi: 10.1016/j. hrthm.2009.10.004.10.1016/j.hrthm.2009.10.004
  68. 69. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J. 2004;148:462-466. doi: 10.1016/j.ahj.2004.01.026.10.1016/j.ahj.2004.01.026
  69. 70. Conway DS, Buggins P, Hughes E, Lip GY. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol. 2004;93:1368-1373. doi: 10.1016/j. amjcard.2004.02.032.10.1016/j.amjcard.2004.02.032
  70. 71. Aronson D, Boulos M, Suleiman A, et al. Relation of C-reactive protein and new-onset atrial fibrillation in patients with acute myocardial infarction. Am J Cardiol. 2007;100:753-757. doi: 10.1016/j.amjcard.2007.04.014.10.1016/j.amjcard.2007.04.014
  71. 72. Hwang HJ, Ha JW, Joung B, et al. Relation of inflammation and left atrial remodeling in atrial fibrillation occurring in early phase of acute myocardial infarction. Int J Cardiol. 2011;146:28-31. doi: 10.1016/j.ijcard.2009.05.065.10.1016/j.ijcard.2009.05.065
  72. 73. Ren Y, Zeng RX, Li JJ, et al. Relation of C-reactive protein and new-onset atrial fibrillation in patients with acute myocardial infarction: A systematic review and meta-analysis. Int J Cardiol. 2015;190:268-70. doi: 10.1016/j.ijcard.2015.04.152.10.1016/j.ijcard.2015.04.152
  73. 74. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997;30:1039-1045.10.1016/S0735-1097(97)00254-4
  74. 75. Roy D, Brugada P, Wellens HJ. Atrial tachycardia facilitating initiation of ventricular tachycardia. Pacing Clin Electrophysiol. 1983;6:47-52.10.1111/j.1540-8159.1983.tb06581.x6188124
  75. 76. Gronefeld GC, Mauss O, Li YG, Klingenheben T, Hohnloser SH. Association between atrial fibrillation and appropriate implantable cardioverter defibrillator therapy: results from a prospective study. J Cardiovasc Electrophysiol. 2000;11:1208-14.10.1046/j.1540-8167.2000.01208.x11083241
  76. 77. Vukmirović M, Bošković A, Tomašević Vukmirović I, et al. Predictions and Outcomes of Atrial Fibrillation in the Patients with Acute Myocardial Infarction. Open Medicine. 2017;12:115-124. doi: 10.1515/med-2017-0018.10.1515/med-2017-0018544440428730170
  77. 78. Munger TM, Dong YX, Masaki M, et al. Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation. J Am Coll Cardiol. 2012;60:851-860. doi: 10.1016/j.jacc.2012.03.042.10.1016/j.jacc.2012.03.042
  78. 79. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation, evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol. 2001;56:375-380.10.2143/AC.56.6.2005701
  79. 80. Parashar S, et al. New-onset atrial fibrillation after acute myocardial infarction and its relation to admission biomarkers (from the TRIUMPH registry). Am J Cardiol. 2013;112:1390-1395.10.1016/j.amjcard.2013.07.006
  80. 81. Crenshaw BS, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol. 1997;30:406-413.10.1016/S0735-1097(97)00194-0
  81. 82. Kinjo K, Sato H, Sato H, Ohnishi Y, Hishida E, Nakatani D. Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol. 2003;92:1150-1154.10.1016/j.amjcard.2003.07.02114609587
  82. 83. Park MJ, Jung JI, Oh YS, Youn HJ. Assessment of the structural remodeling of the left atrium by 64-multislice cardiac CT: comparative studies in controls and patients with atrial fibrillation. Int J Cardiol. 2012;159:181-186. doi: 10.1016/j. ijcard.2011.02.053.10.1016/j.ijcard.2011.02.05321420185
  83. 84. Jabre P, Jouven X, Adnet F, et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation. 2011;123:2094-2100. doi: 10.1161/ CIRCULATIONAHA.110.990192.10.1161/CIRCULATIONAHA.110.990192314291421536994
  84. 85. Podolecki T, Lenarczyk R, Kowalczyk J, et al. Effect of type of atrial fibrillation on prognosis in acute myocardial infarction treated invasively. Am J Cardiol. 2012;109:1689-1693. doi: 10.1016/j.amjcard.2012.02.009.10.1016/j.amjcard.2012.02.00922440129
  85. 86. Rene AG, Généreux P, Ezekowitz M, et al. Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). Am J Cardiol. 2014;113:236-242.10.1016/j.amjcard.2013.09.01624176066
  86. 87. Guenancia C, Stamboul K, Garnier F, et al. Obesity and newonset atrial fibrillation in acute myocardial infarction: a gender specific risk factor. Int J Cardiol. 2014;176:1039-1041. doi: 10.1016/j.ijcard.2014.07.291.10.1016/j.ijcard.2014.07.29125156840
  87. 88. Siu CW, Jim MH, Ho HH, Miu R, Lee SW, Lau CP. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. Chest. 2007;132:44-49. doi: 10.1378/chest.06-2733.10.1378/chest.06-273317400657
  88. 89. Laurent G, Dentan G, Moreau D, Zeller M, Laurent Y, Vincent- Martin M. Atrial fibrillation during myocardial infarction with and without ST segment elevation. Arch Mal Coeur Vaiss. 2005;98:608-614.
  89. 90. Kosmidou I, Chen S, Kappetein AP, et al. New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial. J Am Coll Cardiol. 2018;71:739-748. doi: 10.1016/j. jacc.2017.12.012.10.1016/j.jacc.2017.12.01229447735
  90. 91. Echahidi N, Pibarot P, O’Hara G, Mathieu P. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. 2008;51:793-801. doi: 10.1016/j. jacc.2007.10.043.10.1016/j.jacc.2007.10.04318294562
  91. 92. Chelazzi C, Villa G, De Gaudio AR. Postoperative Atrial Fibrillation. ISRN Cardiology. 2011;2011:203179. doi:10.5402/2011/203179.10.5402/2011/203179326250822347631
  92. 93. Alawami M, Chatfield A, Ghashi R, Walker L. Atrial fibrillation after cardiac surgery: Prevention and management: The Australasian experience. Journal of the Saudi Heart Association. 2018;30:40-46. doi: 10.1016/j.jsha.2017.03.008.10.1016/j.jsha.2017.03.008574403129296063
  93. 94. Alqahtani AAR. Atrial Fibrillation Post Cardiac Surgery Trends Toward Management. Heart Views : The Official Journal of the Gulf Heart Association. 2010;11:57-63. doi: 10.4103/1995- 705X.73212.10.4103/1995-705X.73212300091321187998
DOI: https://doi.org/10.2478/jce-2018-0020 | Journal eISSN: 2457-5518 | Journal ISSN: 2457-550X
Language: English
Page range: 123 - 132
Submitted on: Aug 19, 2018
Accepted on: Sep 11, 2018
Published on: Nov 7, 2018
Published by: Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2018 Diana Opincariu, Iulia Monica Chițu, published by Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.